Vanguard Group Inc. Has $1.37 Billion Stake in United Therapeutics Corporation (NASDAQ:UTHR)

Vanguard Group Inc. lifted its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 0.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,457,135 shares of the biotechnology company's stock after purchasing an additional 15,312 shares during the period. Vanguard Group Inc. owned approximately 9.88% of United Therapeutics worth $1,374,001,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. iA Global Asset Management Inc. purchased a new position in United Therapeutics in the first quarter worth approximately $199,000. New Age Alpha Advisors LLC lifted its stake in United Therapeutics by 97.6% in the first quarter. New Age Alpha Advisors LLC now owns 9,162 shares of the biotechnology company's stock worth $2,824,000 after acquiring an additional 4,525 shares during the last quarter. Ruffer LLP lifted its stake in United Therapeutics by 25.5% in the first quarter. Ruffer LLP now owns 14,374 shares of the biotechnology company's stock worth $4,431,000 after acquiring an additional 2,925 shares during the last quarter. Cumberland Partners Ltd lifted its stake in United Therapeutics by 84.2% in the first quarter. Cumberland Partners Ltd now owns 3,500 shares of the biotechnology company's stock worth $1,079,000 after acquiring an additional 1,600 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in United Therapeutics by 27.5% in the first quarter. PNC Financial Services Group Inc. now owns 4,059 shares of the biotechnology company's stock worth $1,251,000 after acquiring an additional 875 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity

In other United Therapeutics news, Director Nilda Mesa sold 645 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the sale, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at $10,297,208.76. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,681 shares of company stock valued at $24,618,359 in the last 90 days. Company insiders own 10.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on UTHR. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Bank of America reduced their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Morgan Stanley reduced their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. UBS Group boosted their price objective on shares of United Therapeutics from $385.00 to $415.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, HC Wainwright set a $400.00 price objective on shares of United Therapeutics and gave the stock a "buy" rating in a research report on Thursday, July 31st. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $382.00.

United Therapeutics Stock Performance

UTHR traded up $8.33 during trading on Wednesday, hitting $309.72. The stock had a trading volume of 579,471 shares, compared to its average volume of 520,965. The firm has a market capitalization of $13.97 billion, a P/E ratio of 12.09, a PEG ratio of 4.55 and a beta of 0.57. The company's 50-day moving average price is $295.69 and its 200 day moving average price is $310.03. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The business's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same period last year, the company earned $5.85 earnings per share. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.